[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345234-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345234-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mirbit-a-rules-based-single-sample-serum-mirna-classifier-for-pan-cancer-detection-with-multi-cohort-validation","miRBiT: a rules-based single-sample serum miRNA classiﬁer for pan-cancer detection with multi-cohort validation","","Liquid biopsy provides a minimally invasive route for early cancer diagnosis. MicroRNAs (miRNAs) are small non-coding RNAs with stable expression and dysregulation across physiological states, making them strong diagnostic candidates. Existing miRNA cancer classifiers often depend on cohort-based comparisons, which constrains clinical translation. miRBiT introduces a miRNA rules-based single-sample classifier trained on 16,190 samples, evaluated on nine independent datasets, and validated on eight disease cohorts using intra-sample expression signatures to distinguish cancer from non-cancer. An interactive web tool, miRBiT Explorer, visualizes serum miRNA patterns across 46,349 samples, supporting personalized screening and early detection at scale.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mirbit-a-rules-based-single-sample-serum-mirna-classifier-for-pan-cancer-detection-with-multi-cohort-validation/345234/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mirbit-a-rules-based-single-sample-serum-mirna-classifier-for-pan-cancer-detection-with-multi-cohort-validation/345234.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does miRBiT address in miRNA-based cancer detection?","Question",{"text":63,"@type":64},"Existing miRNA classifiers largely rely on cohort-based comparisons, which limits clinical utility for single-patient decisions. miRBiT is designed as a rules-based single-sample classifier using intra-sample miRNA expression signatures.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is miRBiT trained, tested, and validated?",{"text":68,"@type":64},"miRBiT is trained on 16,190 samples, tested across nine independent datasets, and further validated on eight distinct disease cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What additional resource is provided to support interpretation of results?",{"text":72,"@type":64},"miRBiT Explorer is an interactive web application that visualizes and validates serum miRNA expression patterns across 46,349 samples.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345234,1790602926,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Brieﬁngs in Bioinformatics, 2026, 27, bbag189 [https://doi.org/10.1093/bib/bbag189](https://doi.org/10.1093/bib/bbag189)  \nPublished: 25 April 2026  \nCase Study  \nmiRBiT: a rules-based single-sample serum miRNA classiﬁer for pan-cancer detection with multi-cohort validation  \nPandikannan Krishnamoorthy1 , Madhavan Parthasarathy1 , Nilanjana Das1 , Athira S. Raj1 , Ganakalyan Behera2 , Ashok Kumar3 ,  \nVikas Gupta2 , Saikat Das4 , Himanshu Kumar 1 , 5 , *  \n1 Department of Biological Sciences, Laboratory of Immunology and Infectious Disease Biology, Indian Institute of Science Education and Research (IISER) Bhopal, Bhopal Bypass Road, Bhauri, Bhopal-462066, Madhya Pradesh, India  \n2 Department of Otorhinolaryngology (ENT)– Head & Neck Surgery, All India Institute of Medical Sciences (AIIMS), Bhopal, Saket Nagar, Bhopal-462020, Madhya Pradesh, India  \n3 Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bhopal, Saket Nagar, Bhopal-462020, Madhya Pradesh, India  \n4 Department of Radiation Oncology, All India Institute of Medical Sciences (AIIMS), Bhopal, Saket Nagar, Bhopal-462020, Madhya Pradesh, India  \n5 Laboratory of Host Defense, WPI Immunology, Frontier Research Centre, Osaka University, Osaka 5650871, Japan  \n*Corresponding author. Department of Biological Sciences, Laboratory of Immunology and Infectious Disease Biology, Indian Institute of Science Education and Research (IISER) Bhopal, AB-3, Room No.  \n220, Bhopal By-pass Road, Bhauri, Bhopal, MP 462066, India. E-mail: [hkumar@iiserb.ac.in](hkumar@iiserb.ac.in).  \nAbstract  \nLiquid biopsy offers a minimally invasive approach to early cancer diagnosis. MicroRNAs (miRNAs) are small, non-coding RNAs showing excellent diagnostic potential due to their stability and dysregulation upon different physiological conditions. However, existing miRNAbased cancer classifiers rely on cohort-based comparisons, limiting their clinical utility. Extensive analyses in this study present miRNA binary trend (miRBiT), a miRNA rules-based single-sample classifier, trained on 16,190 samples, tested across nine independent datasets, and further validated on 8 distinct disease cohorts. miRBiT utilizes miRNA expression signatures at an intra-sample level to classify ‘cancer’and ‘non_cancer’ samples, including healthy and other diseases with high sensitivity and specificity, enabling personalized predictions. Additionally, an interactive web application, miRBiT Explorer serum miRNA expression resource, is developed to visualize and validate serum miRNA expression patterns in 46,349 samples. This study highlights the potential of miRNAs in robust cancer classification, enabling personalized, minimally invasive cancer screening and early detection at an unprecedented scale.  \nGraphical abstract  \nKeywords microRNAs (miRNAs) biomarkers, single-sample classifier (SSC), pan-cancer detection, liquid biopsy, machine learning classifier, early cancer diagnosis  \n• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •   \nReceived: September 10, 2025 . Revised: February 12, 2026 . Accepted: March 31, 2026  \n© The Author(s) 2026 . Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please [contact journals.permissions@oup.com](contact journals.permissions@oup.com).","cbCaieWqmrUldczV","https://ap.wps.com/l/cbCaieWqmrUldczV","pdf",2453564,16,"English","# Introduction\n## Liquid biopsy and early cancer diagnosis\n## Challenges for existing miRNA classifiers\n## Data and resource gaps addressed by miRBiT\n# Abstract\n# Keywords","[{\"question\":\"What problem does miRBiT address in miRNA-based cancer detection?\",\"answer\":\"Existing miRNA classifiers largely rely on cohort-based comparisons, which limits clinical utility for single-patient decisions. miRBiT is designed as a rules-based single-sample classifier using intra-sample miRNA expression signatures.\"},{\"question\":\"How is miRBiT trained, tested, and validated?\",\"answer\":\"miRBiT is trained on 16,190 samples, tested across nine independent datasets, and further validated on eight distinct disease cohorts.\"},{\"question\":\"What additional resource is provided to support interpretation of results?\",\"answer\":\"miRBiT Explorer is an interactive web application that visualizes and validates serum miRNA expression patterns across 46,349 samples.\"}]","miRBiT: a rules-based single-sample serum miRNA classiﬁer for pan-cancer detection with multi-cohort validation | PDF",1790056908,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b07f454e53a132204c5038a9acb1fe0.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7213d2abab884c474a36d709bdb9a95.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd2f0d80c1417f4df2630fa41c170cf7.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ae0277fa8c6e90aa8d2bc36d41172c7.webp",980,1287]